Pfizer vs. Moderna mRNA patent strategies and pipelines

A duopoly built on 73 pipeline candidates

Pfizer/BioNTech and Moderna together control more than 90% of clinical-stage mRNA vaccine development, with 32 and 41 pipeline candidates respectively — a combined total of 73 programs spanning infectious diseases, oncology, and rare diseases. This concentration of validated mRNA expertise has created a structural duopoly that secondary players such as CureVac and Sanofi have been unable to break, despite holding meaningful lipid nanoparticle (LNP) patent portfolios of their own.

Both companies achieved regulatory approval for COVID-19 vaccines in December 2020 — Pfizer/BioNTech’s Comirnaty (BNT162b2) first, followed days later by Moderna’s Elasomeran (mRNA-1273). That simultaneous proof-of-concept moment set the stage for a platform race that now extends into influenza, RSV, CMV, and personalised cancer vaccines. According to WIPO, mRNA-related patent filings accelerated sharply after 2020, reflecting the technology’s newly validated commercial potential.

The mRNA vaccine market is projected to exceed $10 billion annually by 2030, with combination vaccines and oncology applications representing the highest growth segments beyond endemic COVID-19 maintenance. Flu/COVID combination vaccines alone represent a potential $5–10 billion annual market by 2028, making the 2025–2026 approval window a critical competitive inflection point for both companies.

Four phases of mRNA platform evolution (2015–2026)

The mRNA vaccine technology roadmap divides cleanly into four phases, each defined by a distinct scientific or commercial threshold. Understanding this arc is essential for anticipating where the next competitive advantages will emerge — and which patent positions will prove decisive.

Phase I: Foundation (2015–2019) — Platform Validation

The foundational period centred on solving two problems that had blocked mRNA therapeutics for decades: innate immune activation and delivery. Nucleoside modification breakthroughs — specifically pseudouridine incorporation — reduced the inflammatory response that had previously made mRNA unsuitable for human use. Simultaneously, Moderna and BioNTech established ionizable lipid nanoparticle (LNP) formulations as the standard delivery system. A pivotal licensing event occurred when Acuitas Therapeutics licensed its ALC-0315 ionizable lipid to BioNTech, establishing a dependency that would later become central to patent litigation. By 2019, the first mRNA influenza vaccine candidates had entered Phase 1 trials.

Phase II: COVID-19 Acceleration (2020–2021) — Proof of Concept

Comirnaty received FDA Emergency Use Authorisation in December 2020, followed days later by Elasomeran. Both companies then initiated variant-adapted programs — BA.1, BA.4/BA.5, XBB.1.5, and KP.2-adapted formulations — demonstrating the platform’s core commercial advantage: rapid strain updates within 6–8 weeks from sequence identification to clinical material. According to the FDA, this speed-to-update capability has no precedent in traditional vaccine development.

Phase III: Platform Diversification (2022–2024) — Beyond COVID-19

Both companies launched combination flu/COVID vaccine programs in 2022. The most significant clinical milestone of this phase came from the Phase 2b KEYNOTE-942 trial in 2023, which showed that Moderna’s mRNA-4157 personalised cancer vaccine combined with pembrolizumab produced a 44% reduction in melanoma recurrence or death risk compared with pembrolizumab alone. Moderna’s mRESVIA (mRNA-1345) then became the first approved mRNA RSV vaccine in May 2024, for adults aged 60 and older — a landmark that validated the platform’s reach beyond COVID-19.

Phase IV: Commercial Maturity (2025–2026) — Multi-Indication Platforms

The current phase is defined by regulatory submissions for combination vaccines and late-stage oncology readouts. Moderna submitted mRNA-1083 (flu/COVID combination) for regulatory review in 2024, with approval expected in 2026 following the FDA’s requirement for flu efficacy data. Pfizer/BioNTech received FDA Fast Track designation for its single-dose flu/COVID combination vaccine (PF-07926307), with Phase 3 ongoing. Both companies’ personalised cancer vaccine programs are expected to deliver Phase 3 interim analyses in 2025–2027.

Pfizer/BioNTech: oncology-first diversification and licensed IP

Pfizer/BioNTech’s post-COVID strategy is defined by a concentrated bet on personalised cancer vaccines, leveraging Pfizer’s global commercial infrastructure and BioNTech’s mRNA engineering capabilities. The V940 platform — also called Intismeran Autogene — encodes up to 34 patient-specific neoantigens per dose, making each vaccine unique to the individual patient’s tumour mutation profile.

The oncology pipeline is the broadest of any mRNA company at the Phase 3 stage. V940 is currently in Phase 3 trials for melanoma (INTerpath-001) and NSCLC (INTerpath-002), both in combination with pembrolizumab. Phase 2 programs cover renal cell carcinoma and bladder cancer. BNT-116, an off-the-shelf mRNA cancer vaccine targeting shared NSCLC antigens, is in Phase 2 — providing a lower-cost, faster-manufacturing complement to the individualised V940 approach.

“Pfizer/BioNTech’s V940 (Intismeran Autogene) personalised cancer vaccine encodes up to 34 patient-specific neoantigens and is in Phase 3 trials across melanoma, NSCLC, and renal cell carcinoma simultaneously — the broadest late-stage oncology mRNA footprint of any company.”

On the infectious disease side, the flu/COVID combination vaccine (PF-07926307) targets four influenza strains plus COVID-19 in a single mRNA dose. It received FDA Fast Track designation in December 2022 and is now in Phase 3. Pfizer/BioNTech also maintains pandemic influenza preparedness programs, including H5N1 mRNA vaccine candidates in early clinical development. The company’s variant adaptation capability — producing updated COVID-19 formulations within 6–8 weeks — has been demonstrated repeatedly through the Omicron BA.1, BA.4/BA.5, XBB.1.5, and KP.2-adapted approvals, with LP.8.1-adapted data already reported for the 2025–2026 formula.

Moderna: respiratory-first expansion and proprietary LNP

Moderna’s post-COVID strategy prioritises breadth across respiratory indications before expanding into oncology, underpinned by a proprietary technology stack that includes its in-house SM-102 ionizable lipid. With 41 pipeline candidates — the largest mRNA portfolio in the industry — Moderna has more programs in late-stage development than any competitor and has already achieved a second approved product in mRESVIA.

The respiratory franchise is the commercial engine. Elasomeran (mRNA-1273) remains the foundation, with next-generation mRNA-1283 offering a refrigerator-stable (2–8°C) formulation that addresses one of the original platform’s most significant distribution limitations. The mRNA-1083 flu/COVID combination has completed Phase 3 and been submitted for regulatory review, with approval expected in 2026 after the FDA requested flu-specific efficacy data. The mRNA-1010 seasonal influenza quadrivalent vaccine (targeting two A strains and two B strains) has completed enrollment in its Phase 3 efficacy trial, with interim data expected mid-2025.

The CMV program (mRNA-1647) represents one of the most significant unmet needs in the pipeline. Cytomegalovirus is the leading infectious cause of congenital disability in the United States, according to the CDC, yet no approved vaccine exists. The Phase 3 CMVictory trial is fully enrolled, with 36-month antibody durability data showing titers remaining above baseline. An efficacy readout is expected in 2025, though the Data Safety Monitoring Board recommended continuation after an initial interim analysis did not meet the early efficacy criterion.

In oncology, mRNA-4157 (co-developed with Merck) is in Phase 3 for melanoma following the landmark KEYNOTE-942 Phase 2b result showing a 44% reduction in recurrence or death risk. Early-stage NSCLC trials are underway. An off-the-shelf cancer vaccine, mRNA-4203, targeting shared tumor antigens across multiple cancer types, is in Phase 1. Moderna’s rare disease programs — mRNA-3705 for methylmalonic acidemia and mRNA-3927 for propionic acidemia — extend the platform into enzyme replacement-like applications, demonstrating the versatility of the mRNA delivery system beyond vaccines. The NIH has supported foundational research underpinning several of these rare disease applications.

The patent battleground reshaping the mRNA IP landscape

Moderna filed patent infringement claims against Pfizer/BioNTech in 2022, alleging that Comirnaty copied foundational mRNA and LNP technology that Moderna had developed and patented before the pandemic. The lawsuit, filed in both the United States and Europe, remains unresolved as of 2026 — making it one of the most consequential IP disputes in pharmaceutical history.

Moderna’s core claims centre on nucleoside-modified mRNA technology and lipid formulation ratios. Pfizer/BioNTech’s defence rests on its licensing arrangements with Acuitas Therapeutics and the University of Pennsylvania, arguing that its technology was independently developed or properly licensed from third parties. The outcome could determine licensing economics across the entire mRNA industry — a potential cross-licensing settlement would likely reshape how future mRNA vaccine developers access foundational IP.

Beyond the litigation, the broader patent landscape reveals meaningful innovation activity outside the two market leaders. CureVac holds 50 or more patents on LNP technology and is pivoting to next-generation mRNA approaches after its CVnCoV COVID-19 candidate was discontinued. Sanofi holds LNP formulation patents through its partnership-based development model. Academic institutions — including the University of Pennsylvania (nucleoside modification) and Johns Hopkins University (LNP-mRNA therapeutics) — hold foundational patents that underpin both companies’ core technologies. The EPO has been a key venue for several of these foundational patent grants and the ongoing Moderna-Pfizer/BioNTech dispute.

A critical structural distinction in IP strategy: Pfizer/BioNTech operates a partnership-driven model, licensing in key components and co-owning patents with academic partners. Moderna pursues vertical integration — developing its SM-102 ionizable lipid in-house and aggressively enforcing its patent estate. This divergence means Moderna bears higher internal R&D costs but retains full control of its technology stack, while Pfizer/BioNTech gains commercial flexibility at the cost of dependency on third-party licensors.

Where the platforms diverge: technology, stability, and scale

Despite sharing the same core mRNA modification chemistry — N1-methylpseudouridine incorporation — and the same basic antigen design principles for COVID-19 (full-length spike protein with P2 proline stabilisation), Pfizer/BioNTech and Moderna have made meaningfully different choices across LNP composition, storage stability, combination vaccine ambition, and manufacturing architecture.

The refrigerator-stability gap is commercially significant. Comirnaty’s original ultra-cold chain requirement created logistical barriers in low- and middle-income countries that Moderna’s next-generation mRNA-1283 formulation is designed to eliminate. This storage advantage, combined with Moderna’s modular manufacturing approach, positions the company more strongly for global market expansion — particularly as WHO frameworks push for broader mRNA technology transfer to lower-income nations.

Pfizer/BioNTech’s countervailing advantage is commercial reach. Pfizer’s global sales force operates in more than 150 countries, providing distribution infrastructure that Moderna — still building its commercial organisation — cannot match in the near term. This asymmetry means that even if Moderna achieves earlier regulatory approvals in some combination vaccine categories, Pfizer/BioNTech may capture greater market share through superior access to healthcare systems worldwide.

Both companies’ personalised cancer vaccine programs share a key technical constraint: manufacturing complexity. Each individualised dose requires sequencing the patient’s tumour, selecting neoantigens using proprietary algorithms, and synthesising a bespoke mRNA sequence — a process that takes weeks and carries significant cost. Whether this can be scaled to commercial viability, even with positive Phase 3 efficacy data, remains the central uncertainty for the oncology segment. PatSnap’s innovation intelligence platform tracks life sciences R&D intelligence across these programs, including manufacturing patent filings that may signal how each company is addressing this bottleneck.

For R&D strategists and IP professionals seeking to navigate this landscape, the PatSnap patent analytics platform provides comprehensive coverage of LNP formulation filings, neoantigen algorithm patents, and manufacturing process claims across all major mRNA developers — enabling competitive intelligence that goes beyond publicly available pipeline disclosures.